Give!
To continue to advance cellular therapy for the treatment of leukemia, lymphoma, and other life-threatening diseases, CIBMTR needs your support. Contributions from individuals and corporations are essential to support research that improves outcomes and quality of life for transplant recipients.
GIVE
Learn more about:
Corporate support
To help make our life-saving research possible, CIBMTR provides opportunities for foundations, companies, and other industry collaborators to support our work. We invite you to learn more about our membership program and specific studies and event opportunities.
Corporate support opportunities
In addition to our Corporate Membership Program, we offer organizations the opportunity to support CIBMTR through:
CIBMTR Annual Meeting Support
Contributions to this program support the annual Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings). This educational conference focuses on timely issues in blood and marrow transplantation and other cellular therapies. Its program includes scientific plenary sessions, poster sessions, and comprehensive workshops. The meeting provides exhibiting opportunities for corporations with an interest in transplantation and other cellular therapies as well as corporate-supported satellite sessions.
CIBMTR Special Project Funding
Contributions to this program help to support specific areas of research that may be of special interest to the community. CIBMTR is currently coordinating more than 250 studies on various diseases and transplant-related topics. These studies are being used to improve transplant outcomes for serious diseases such as leukemia, lymphoma, multiple myeloma, solid tumors, neuroblastoma, severe aplastic anemia, sickle cell disease, Fanconi anemia, congenital immune deficiencies, and congenital metabolic disorders.
To learn more about these and other support opportunities, contact:
Sherry L. Fisher
Director of Advancement
CIBMTR – Medical College of Wisconsin
9200 W. Wisconsin Ave.
Milwaukee, WI 53226
E-mail: slfisher@mcw.edu
Private contributions
CIBMTR needs your help to continue our life-saving research in blood and marrow transplantation and other cellular therapies. We are proud of the support we receive from our corporate and government supporters. However, private contributions are essential for us to continue our work.
How to make a gift
If you would like to make a gift to CIBMTR, please make an online donation or send the completed Private Contribution Form (PDF) by fax, mail, or e-mail to:
Sherry L. Fisher
Director of Advancement
CIBMTR – Medical College of Wisconsin
9200 W. Wisconsin Ave
Milwaukee, WI 53226
slfisher@mcw.edu
Checks should be made payable to The Medical College of Wisconsin/CIBMTR. Contributions are tax-deductible as allowed by law.
For further information on ways to participate as a contributor, including gifts of stocks or company-matching gifts, please contact Sherry Fisher using the information listed above.
Fundraising programs
As a contributor, you can direct your gift to one of our fundraising programs:
- CIBMTR General Support Fund: Contributions to this program help to support general operations. These funds significantly enhance our ability to maintain and develop our database in order to ensure the scientific integrity of our research program. These funds also allow us to respond in a timely manner to emerging areas of research not supported by our federal funding. Donors may wish to make their gift in honor or in memory of a special person.
- CIBMTR Mortimer M. Bortin Endowment: The Mortimer M. Bortin Endowment fund was established to honor Dr. Mortimer M. Bortin’s commitment to international scientific collaboration. Dr. Bortin was one of the founders of the IBMTR and served as its Scientific Director from 1972-1994. Donors may wish to make their gift in honor or in memory of a special person.
Our Supporters
- AbbVie
- Actinium Pharmaceuticals, Inc.
- Adaptive Biotechnologies Corporation
- ADC Therapeutics
- Adienne SA
- Alexion
- AlloVir, Inc.
- Amgen, Inc.
- Astellas Pharma US
- AstraZeneca
- Atara Biotherapeutics
- Autolus Limited
- BeiGene
- BioLineRX
- Blue Spark Technologies
- bluebird bio, inc.
- Blueprint Medicines
- Bristol Myers Squibb Co.
- CareDx Inc.
- Caribou Biosciences, Inc.*
- CSL Behring*
- CytoSen Therapeutics, Inc.
- DKMS
- Editas Medicine*
- Elevance Health*
- Eurofins Viracor, DBA Eurofins Transplant Diagnostics
- Gamida-Cell, Ltd.*
- Gift of Life Biologics
- Gift of Life Marrow Registry
- HistoGenetics
- In8bio*
- Incyte Corporation*
- Iovance
- Janssen Research & Development, LLC
- Janssen/Johnson & Johnson
- Jasper Therapeutics
- Jazz Pharmaceuticals, Inc.*
- Karius
- Kashi Clinical Laboratories
- Kiadis Pharma
- Kite, a Gilead Company
- Kyowa Kirin
- Labcorp
- Legend Biotech
- Mallinckrodt Pharmaceuticals
- Med Learning Group
- Medac GmbH
- Merck & Co.
- Millennium, the Takeda Oncology Co.
- Miller Pharmacal Group, Inc.
- Miltenyi Biomedicine
- Miltenyi Biotec, Inc.
- MorphoSys
- MSA-EDITLife
- Neovii Pharmaceuticals AG
- Novartis Pharmaceuticals Corporation
- Omeros Corporation
- Orca Biosystems, Inc.
- OriGen BioMedical
- Ossium Health, Inc.
- Pfizer, Inc.
- Pharmacyclics, LLC, An AbbVie Company
- PPD Development, LP
- Registry Partners
- Rigel Pharmaceuticals
- Sanofi*
- Sarah Cannon
- Seagen Inc.
- Sobi, Inc.
- Stemcell Technologies
- Stemline Technologies
- STEMSOFT
- Takeda Pharmaceuticals
- Talaris Therapeutics
- TScan Therapeutics*
- Vertex Pharmaceuticals*
- Vor Biopharma Inc.
- Xenikos BV
*Corporate Member